GIC Re on Saturday reported a 6 per cent drop in net profit to Rs 1,519 crore for the third quarter ended December 2025. The state-owned reinsurance company earned a net profit of Rs 1,621 crore in the October-December period of the last fiscal. Total income of the re-insurer rose to Rs 11,557 crore in the quarter, compared to Rs 10,479 crore in the same quarter a year ago, GIC Re said in a regulatory filing. Gross premium improved to Rs 10,987 crore during the third quarter of the current fiscal against Rs 9,968 crore a year ago period. During the quarter, the premium earned rose to Rs 9,580 crore, as against Rs 8,540 crore in the same period a year ago. The solvency ratio increased to 3.87 from 3.52 at the end of December 2024. Total assets of the company rose to Rs 2,03,414 crore, as against Rs 1,88,953 crore in the same period of previous year. GIC Re is the largest reinsurer in the domestic reinsurance market and leads most of the domestic companies' treaty programmes and .
SBI's Q3FY26 net profit rose 24.5 per cent to ₹21,028 crore on higher NII and non-interest income. The bank raised FY26 credit growth guidance to 13-15 per cent
On a standalone basis, the largest lender in the country reported 24.48 per cent jump in the December quarter net profit at ₹21,028 crore as against ₹16,891 crore in the year-ago period
Q3FY26 company results: Firms including Tinna Rubber and Infrastructure, Autoline Industries, Balkrishna Paper Mills, and VST Tillers Tractors are also to release their October-December earnings today
Gains come on the back of higher India volumes, Netherlands turnaround
JK Tyre reported its highest-ever quarterly revenue in Q3 FY26 as volumes recovered and raw material costs eased, helping profits rebound sharply from a weak base last year
Tata Motors Q3FY26 results: Analysts stay cautiously positive as India PV growth improves, JLR outlook stabilises. Targets range ₹310-₹460.
Transaction charges, which constitute over two-thirds of the total income, fell 12 per cent Y-o-Y. The decline likely reflects lower trading volumes and market activity
Surge in Tata Steel's Q3 profit comes on the back of improving profit margin, which rose to 4.79 per cent in Q3FY26, from 0.55 per cent in the same quarter last year
JM Financial Ltd has reported a 50 per cent jump in its consolidated profit after tax of Rs 313 crore for the third quarter ended December 2025, driven by strong performance in its corporate advisory, capital markets and private business segments. The company had posted a profit after tax (PAT) of Rs 209 crore in the same period of the last year, the Mumbai-based company said in a regulatory filing on Thursday. For the nine months ended December 2025, JM Financial's PAT jumped 69 per cent year-on-year to Rs 1,037 crore, it added. Fees and commission income increased by 32 per cent to Rs 306 crore, while operating PAT rose 17 per cent to Rs 244 crore. Its consolidated net worth stood at Rs 10,418 crore, up 17 per cent. Vishal Kampani, Vice Chairman and Managing Director, JM Financial Ltd, said the company crossed Rs 1,000 crore in PAT during the first nine months, with strong execution of strategies across businesses. "Private Markets, which provides a natural hedge to volatility i
Volume growth of tyre companies remained healthy, supported by robust momentum in both the OEM and replacement segments, along with continued premiumisation, said Ceat management.
Jubilant Pharmova shares: The scrip fell as much as 4.4 per cent to ₹931 per share on the National Stock Exchange (NSE)
MRF's Q3 revenue from operations increased 15 per cent Y-o-Y to ₹8,050.43 crore from ₹7,000.82 crore in Q3FY25. Sequentially, revenue was up 9.1 per cent from ₹7,378.72 crore in Q2FY26
Physicswallah had reported a 33 per cent year-on-year (Y-o-Y) increase in its net profit to 102.3 crore compared to ₹76.7 crore in the year-ago period
AAVAS Financiers stock quoted lower for the eight straight trading day, and has plunged 14 per cent during this period.
The stock rose as much as 6.2 per cent to ₹1,729, the highest level since January 12 on the National Stock Exchange (NSE)
Sai Life Sciences has invested ₹405 crore in capital expenditure so far, against its planned outlay of ₹700 crore for FY26
Alembic Pharma shares today: Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share
The scrip increased as much as 4.1 per cent to ₹271.80, the highest level since January 5 on the National Stock Exchange (NSE)
Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market